Dragon Jade International Announces New Treatment for Diabetes
Hong Kong, September 24, 2014 -- Dragon Jade International Limited (OTCQB:DGJI) (the “Company”), has been acquiring several long established and proven Chinese herbal medicinal products from several long standing Chinese medicine practitioners in China, Hong Kong regions, Taiwan and the USA. The Company is pleased to announce today that it has recently accredited and accepted another Chinese herbal formula that has clinically been proven to treat diabetes. Specifically, the new product has successfully lowered the AC-glucose level and HbA1C of diabetes patients. Consumption of the herbal medicine has demonstrated significant health improvements in patients with Diabetes Mellitus. Diabetes Mellitus is an autoimmune disease that permanently destroys beta cells in the pancreas, meaning that the body can no longer produce insulin, a hormone that enables people to get energy from food. Lack of insulin production by the pancreas makes diabetes a particularly difficult medical condition to treat. Scientists believe that both genetic factors and environmental triggers are involved in its cause. Its onset has nothing to do with diet or lifestyle.
Diabetes Mellitus is a serious problem in most of developed and developing countries. Three hundred and forty seven million people worldwide suffer from diabetes, in 2010 an estimated 3.4 million people died from consequences of fasting high blood sugar. The World Health Organization projects the diabetes growth rates for 2000-2030 for the key geographic areas are: US (102%), Europe (43%), Asia Pacific (130%) and Africa/Middle East (162%). In 2012, the total sales of worldwide diabetes medicine were nearly 35 billion US dollars. Standard and Poor's estimated that the total sales would be more than 58 billion US dollars in 2018.
The Company intends to manufacture and distribute the herbal diabetes medicine in tablet form. It is expected that this naturopathic product will significantly benefit diabetes patients all over the world. It will be another important addition to the Company’s ever-growing product line of natural healing products.
Dr. Yat Man, Lai, C.E.O. of Dragon Jade International Limited said, "Developing Chinese Medicine for Diabetic Mellitus has provided us with extremely favorable access to diabetes market which we have deemed as a key element of our overall strategy for growth. There are many other components to our strategic aims, but this product sets the stage for our immediate development program and can greatly aid in positioning our company at the forefront of dietary supplement sector."
About Dragon Jade
Dragon Jade International Limited and its subsidiaries ("the Group") focused on identifying, developing and marketing the next generation of herbal and natural products that improve people's lives. The Group is positioned to leverage proven resources that allow us to assess, enhance and realize the commercial potential of herbal and biotechnological discoveries. The Group strives to develop and offer to the market the broadest selection of cost-effective healthy living products, which shall deliver substantial returns to investors. More information on Dragon Jade, visit the Company's website: http://www.dgjigroup.com.
Safe Harbor Statement
This release includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as DGJI or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
Dr. Yat Man, Lai